Design an outline for the review of the neuroactive transdermal drug delivery systems
DOI:
https://doi.org/10.63682/jns.v14i32S.9624Keywords:
Anti-depressant, Anti-pychotic, Parkinson’s disease, transdermal drug delivery system, Clinical trial, First-pass metabolism and NeuroactiveAbstract
Background: Transdermal drug delivery began in the 1960s with skin absorption studies, leading to the commercialisation of scopolamine and nitroglycerin patches in the 1970s to maintain steady drug levels. Oral MAOIs carry severe risks, such as tyramine-induced hypertensive crises, prompting alternative approaches. Selegiline, a selective MAO-B inhibitor, was reformulated as a transdermal patch to bypass first-pass metabolism, achieving brain therapeutic levels with reduced peripheral exposure.
Methods: A comprehensive systematic literature search identified 21 potential drug candidates suitable for transdermal delivery. Among these, several agents emerged as particularly promising due to their pharmacokinetic properties and therapeutic relevance. Notable examples in the clinical trial stage includes citalopram, the combination of bupropion with nortriptyline, nicotine, selegiline, ketamine, sertraline, rivastigmine, raloxifene, buprenorphine, fluoxetine, and rotigotine. These drugs are considered ideal candidates for transdermal drug delivery systems because they can benefit from bypassing gastrointestinal metabolism, reducing systemic side effects, and maintaining steady plasma concentrations. Collectively, the findings highlight a diverse range of psychotropic, neuroactive, and analgesic compounds that may be optimised through patch-based or assisted transdermal technologies, underscoring the growing interest in expanding beyond traditional oral and injectable routes.
Result and Conclusion: A systematic review found that selegiline, Rivastigmine, and rotigotine have received US FDA/EU approval in transdermal patch form.
Downloads
References
Wang Y, Yu X, Zhang P, Ma Y, Wang L, Xu H, Sui D. Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease. Journal of pharmacological sciences. 2018 Sep 1;138 (1):31-7.
Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs & aging. 2006 May;23(5):357-75.
Nguyen J, Ita KB, Morra MJ, Popova IE. The influence of solid microneedles on the transdermal delivery of selected antiepileptic drugs. Pharmaceutics. 2016 Nov 15;8(4):33.
Siafaka PI, Bülbül EÖ, Mutlu G, Okur ME, Karantas ID, Okur NÜ. Transdermal drug delivery systems and their potential in Alzheimer’s disease management. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders). 2020 Jun 1;19(5):360-73.
Sozio P, Cerasa LS, Marinelli L, Di Stefano A. Transdermal donepezil on the treatment of Alzheimer’s disease. Neuropsychiatric disease and treatment. 2012 Aug 20:361-8.
Nguyen J, Ita KB, Morra MJ, Popova IE. The influence of solid microneedles on the transdermal delivery of selected antiepileptic drugs. Pharmaceutics. 2016 Nov 15;8(4):33.
Xiao S, Yan Y, Zhao J, Zhang Y, Feng N. Increased microneedle-mediated transdermal delivery of tetramethylpyrazine to the brain, combined with borneol and iontophoresis, for MCAO prevention. International Journal of Pharmaceutics. 2020 Feb 15;575:118962.
Ferini-Strambi L, Marelli S, Galbiati A. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome. Expert Opinion on Drug Metabolism & Toxicology. 2016 Aug 2;12(8):967-75.
Giladi N. A. 3 Rotigotine (Neupro®), a new non-ergolinic dopamine agonist in a transdermal patch, for early and late stages of Parkinson'ss Disease. Parkinsonism & Related Disorders. 2006 May 1;12:4.
Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurologica Scandinavica. 2003 Nov;108(5):368-73.
Shua-Haim JR, Yap C, Kretov A, Lee P. P2‐411: Results of next‐day crossover study of rivastigmine oral capsules (Exelon) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: A two‐month clinical experience. Alzheimer's & Dementia. 2008 Jul;4:T494.
Ferris S, Meng X, Velting D. Caregiver treatment preference/satisfaction and efficacy among patients in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA) study (P7. 104). Neurology. 2015 Apr 6;84(14_supplement):P7-104.
Asnis GM, Henderson MA. EMSAM (deprenyl patch): how a promising antidepressant was underutilized. Neuropsychiatric disease and treatment. 2014 Oct 6:1911-23.
Elliott WT, Chan J. Selegiline Transdermal System (Emsam®). Internal Medicine Alert. 2006 Apr 29;28(8):62-3.
Trinker FR, Barnett AJ. Trial of a new hypotensive drug—clonidine (“catapres”). Medical Journal of Australia. 1970 Oct;2(15):675-8.
Kim TS, Jin SE, Sun B, Kim MS, Hwang SJ. Comparison of adhesion and dissolution of fentanyl patches: Fentadur® and Durogesic DTrans®. Journal of Pharmaceutical Investigation. 2015 Oct;45(5):475-80.
Kwarcinski M, Cataldo M, Munera C, Dain B. Butrans®(buprenorphine) Transdermal System and 7-day analgesic efficacy. The Journal of Pain. 2012 Apr 1;13(4):S85.
Citrome L, Zeni CM, Correll CU. Patches: established and emerging transdermal treatments in psychiatry. The Journal of clinical psychiatry. 2019 Jul 16;80(4):21174.
Roy S, Das S, Das D, Maji HS, Bose A, Bhattacharjee S, Biswas S, Dinda SC. Transdermal Drug Delivery and Organic Polymers: Current Scenario and Future Prospects. Organic Polymers in Energy‐Environmental Applications. 2024 Nov 4:555-75.
Watkinson AC, Kearney MC, Quinn HL, Courtenay AJ, Donnelly RF. Future of the transdermal drug delivery market–have we barely touched the surface?. Expert opinion on drug delivery. 2016 Apr 2;13(4):523-32.
Raineri R, Binder J, Cohen A, Muller A. Peaceful Uses of Nuclear Energy in Less Industrialized Countries: Challenges, Opportunities, and Acceptance. Energies. 2025 Feb 12;18(4):858.
Md S, Haque S, Sahni JK, Baboota S, Ali J. New non-oral drug delivery systems for Parkinson's disease treatment. Expert opinion on drug delivery. 2011 Mar 1;8(3):359-74.
Moezzi SM, Masoumi Shahrbabak S, Amiri S, Hajihosseini S, Masoudifar R, Mostafa Nejadian E, Akbari Javar H. Transdermal drug delivery systems for psychological disorders. Pharmaceutical Development and Technology. 2025 Oct 1 :1-50.
Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, Varrassi G, Urits I, Viswanath O, Kaye AM, Kaye AD. Buprenorphine and its formulations: a comprehensive review. Health psychology research. 2022 Aug 20;10(3):37517.
Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, Whiteford H. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychological medicine. 2013 Mar;43(3):471-81.
Tabi T, Szökő É, Vecsei L, Magyar K. The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease. Expert opinion on drug metabolism & toxicology. 2013 May 1;9(5):629-36.
Jost WH, Friede M, Schnitker J. Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease. Basal Ganglia. 2012 Dec 1;2(4):S17-26.
Jessen L, Kovalick LJ, Azzaro AJ. The selegiline transdermal system (emsam): A therapeutic option for the treatment of major depressive disorder. Pharmacy and Therapeutics. 2008 Apr;33(4):212.
Sikandar M, Shoaib MH, Yousuf RI, Ahmed FR, Siddiqui F, Saleem MT, Irshad A. Dissolving microneedle patches for transdermal delivery of paroxetine: in-vitro, ex-vivo studies and its PBPK modeling. Therapeutic Delivery. 2025 Sep 2;16(9):835-51.
Sun YY, Ni YJ, Wang RJ, Qin ZC, Liu Z, Xiao LH, Liu YQ. Establishment and validation of a transdermal drug delivery system for the anti-depressant drug citalopram hydrobromide. Molecules. 2024 Feb 7;29(4):767.
McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology. 2006 Nov;189(1):125-33.
Jankovic J, Watts RL, Martin W, Boroojerdi B, SP 512 Rotigotine Transdermal System Clinical Study Group. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Archives of neurology. 2007 May 1;64(5):676-82.
Plakogiannis FM, Hossain MA, inventors; Aequus Pharmaceuticals Inc, assignee. Aripiprazole compositions and methods for transdermal administration. 2018 Jul 13.
Suzuki K, Castelli M, Komaroff M, Starling B, Terahara T, Citrome L. Pharmacokinetic profile of the asenapine transdermal system (HP-3070). Journal of Clinical Psychopharmacology. 2021 May 1;41(3):286-94.
Iwata N, Ishigooka J, Kim WH, Yoon BH, Lin SK, Sulaiman AH, Cosca R, Wang L, Suchkov Y, Agarkov A, Watabe K. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophrenia research. 2020 Jan 1;215:408-15.
Iwata N, Ishigooka J, Naoi I, Matsumoto M, Kanamori Y, Nakamura H, Higuchi T. Long-term safety and efficacy of blonanserin transdermal patches in Japanese patients with schizophrenia: a 52-week open-label, multicenter study. CNS drugs. 2020 Jan;34(1):103-16.
Yamaguchi J, Sadahiro R, Hirayama T, Wada S, Nakahara R, Matsuoka H. Severe behavioral and psychological symptoms of dementia successfully treated at home with a blonanserin transdermal patch: A case report. Neuropsychopharmacology Reports. 2024 Jun;44(2):474-8.
Aggarwal G, Dhawan S, Hari Kumar SL. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug Development and Industrial Pharmacy. 2013 Jan 1;39(1):39-50.
Demurtas A, Nicoli S, Pescina S, Marchitto L, Ragni L, Russo V, Tommasi G, Santi P, Padula C. Development, optimization and ex-vivo evaluation of a transdermal formulation containing trazodone. European Journal of Pharmaceutical Sciences. 2024 Oct 1;201:106874.
Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clinical pharmacokinetics. 1997 Oct;33(4):260-75.
Jastrzębska J, Frankowska M, Smaga I, Hubalewska-Mazgaj M, Suder A, Pieniążek R, Przegaliński E, Filip M. Evaluation of the 5-HT2C receptor drugs RO 60-0175, WAY 161503 and mirtazepine in a preclinical model of comorbidity of depression and cocaine addiction. Pharmacological Reports. 2023 Feb;75(1):99-118.
Barrett JS, Hochadel TJ, Morales RJ, Rohatagi S, DeWitt KE, Watson SK, DiSanto AR. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. American journal of therapeutics. 1996 Oct 1;3(10):688-98.
Van den Eynde V, Abdelmoemin WR, Abraham MM, Amsterdam JD, Anderson IM, Andrade C, Baker GB, Beekman AT, Berk M, Birkenhäger TK, Blackwell BB. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS spectrums. 2023 Aug;28(4):427-40.
Giménez‐Palomo A, Chamdal AK, Gottlieb N, Lotfaliany M, Jokinen T, Bastawy EM, Adlington K, Benachar N, Dodd S, Pacchiarotti I, Vieta E. Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis. Acta Psychiatrica Scandinavica. 2024 Dec;150(6):500-15.
Singh A, Bali A. Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride. Journal of Analytical Science and Technology. 2016 Nov 28;7(1):25.
Coutens B, Yrondi A, Rampon C, Guiard BP. Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine. Psychopharmacology. 2022 Sep;239(9):2735-52.
Bruno A, Morabito P, Spina E, Rosaria Muscatello M. The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Current Neuropharmacology. 2016 Feb 1;14(2):191-9.
Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clinical pharmacokinetics. 1994 Mar;26(3):201-14.
Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991 Feb;41(2):225-53.
Perry CM, Benfield P. Sertraline: an overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs. 1997 Jun;7(6):480-500.
Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS drugs. 2003 Apr;17(5):343-62.
Bryson HM, Wilde MI. Amitriptyline: a review of its pharmacological properties and therapeutic use in chronic pain states. Drugs & aging. 1996 Jun;8(6):459-76.
Deupree JD, Montgomery MD, Bylund DB. Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram. European journal of pharmacology. 2007 Dec 8;576(1-3):55-60.
Leonard BE. A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review. International clinical psychopharmacology. 1987 Oct 1;2(4):281-97.
-.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
